文献速递消化道肿瘤放疗

高剂量放化疗增加直肠癌患者保器官机会并获得满意功能结局

High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer.
PubMed 文献 · Radiat Oncol · 2022-05-18

回顾性分析2006年4月至2017年7月接受根治性盆腔放疗的非转移性直肠腺癌患者57例,中位放疗剂量80 Gy,42例(73.7%)达临床完全缓解,3年总生存率91.4%,中位随访43.5个月。高剂量放化疗显示出有希望的生存结局、可接受的近期和远期不良反应及满意的长期功能结局和生活质量。

要点

  • 57例非转移性直肠腺癌患者接受中位80 Gy放疗联合同期氟尿嘧啶类化疗,42例(73.7%)达临床完全缓解。
  • 3年局部无复发生存率77.3%,3年无远处转移生存率79.2%,3年总生存率91.4%。
  • 肿瘤距肛缘≤3 cm患者括约肌保留率85.3%;21例完成生活质量问卷者总体健康状况评分78.57±17.59。

核心结论

  • 高剂量放化疗显示出有希望的生存结局、可接受的近期和远期不良反应以及满意的长期功能结局和生活质量,作者认为可考虑作为拒绝手术的直肠癌患者的非侵入性替代选择。

研究设计与样本

  • 回顾性研究纳入2006年4月至2017年7月接受根治性盆腔放疗的非转移性直肠腺癌患者57例,中位年龄59.0岁(范围29-84岁)。
  • 分期为I期5例(8.8%)、II期16例(28.1%)、III期36例(63.2%);53例(93.0%)肿瘤位于距肛缘5 cm以内。
  • 全部患者接受氟尿嘧啶类同期放化疗,中位放疗剂量80 Gy(范围60-86 Gy);生存分析采用Kaplan-Meier法,生活质量和功能结局采用EORTC生活质量问卷评估。

主要发现

  • 42例(73.7%)在放化疗后达临床完全缓解;3-4级不良反应共发生于18例(31.6%)患者。
  • 中位随访43.5个月(范围14.9-163.2个月)后,12例(21.1%)出现局部进展,11例(19.3%)发生远处转移。
  • 3年局部无复发生存率77.3%(95% CI 65.7-88.8%),3年无远处转移生存率79.2%(95% CI 68.2-90.2%),3年无进展生存率61.9%(95% CI 48.8-75.0%),3年癌症特异性生存率93.1%(95% CI 85.8-100.0%),3年总生存率91.4%(95% CI 83.6-99.2%)。
  • 肿瘤距肛缘3 cm以内患者末次随访时括约肌保留率为85.3%;远期不良反应主要为肛门出血。
  • 完成生活质量问卷的21例患者总体健康状况评分为78.57±17.59,其中95.2%报告无尿失禁,85.7%报告无大便失禁。

临床怎么用

  • 作者认为,对于拒绝手术的直肠癌患者,高剂量放化疗可考虑作为非侵入性替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High dose chemoradiotherapy offers a curative chance for patients with rectal cancer that are unfit or unwilling to undergo surgical resection, yet its long-term survival and functional outcomes have been rarely investigated. METHODS: Patients with non-metastatic rectal adenocarcinoma who received pelvic radiation for curative intent from April 2006 to July 2017 were retrospectively investigated. Survival rates were analyzed using the Kaplan-Meier method. Quality of life and functional outcomes were evaluated using the EORTC quality of life questionnaire. RESULTS: A total of 57 patients were included, with a median age of 59.0 (range, 29-84) years. The numbers of patients who were diagnosed as stage I, II and III were 5 (8.8%), 16 (28.1%) and 36 (63.2%), respectively. 53 (93.0%) patients had tumor located within 5 cm from the anal verge. All patients received fluorouracil-based concurrent chemoradiotherapy with a median radiation dose of 80 (range, 60-86) Gy. All kinds of grade 3-4 adverse events occurred in 18 (31.6%) patients. 42 (73.7%) patients achieved a clinical complete response after chemoradiotherapy. After a median follow-up of 43.5 (range 14.9-163.2) months, 12 (21.1%) patients had local progression and 11 (19.3%) developed distant metastasis. The 3-year local recurrence-free survival and distant metastasis-free survival were 77.3% (95% CI, 65.7-88.8%) and 79.2% (95% CI, 68.2-90.2%), while the 3-year progression-free survival, cancer-specific survival, overall survival were 61.9% (95% CI, 48.8-75.0%), 93.1% (95% CI, 85.8-100.0%) and 91.4% (95% CI, 83.6-99.2%), respectively. For patients who had tumor located within 3 cm from the anal verge, the sphincter preservation rate was 85.3% at last follow-up. Long-term adverse events mainly were anal blood loss. 21 patients completed the quality-of-life questionnaire and had a score of the global health status of 78.57 ± 17.59. Of them, 95.2% reported no urinary incontinence and 85.7% reported no fecal incontinence. CONCLUSIONS: High dose chemoradiation demonstrated promising survival outcomes with acceptable short-term and long-term side effects, and satisfying long-term functional outcomes and quality of life. It could be considered as a non-invasive alternative for rectal cancer patients who refuse surgery.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang QX, Zhang S, Xiao WW, et al. High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer. Radiat Oncol. 2022. PMID: 35585551. doi:10.1186/s13014-022-02066-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。